California State Teachers Retirement System increased its stake in Spark Therapeutics Inc (NASDAQ:ONCE) by 3.8% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 42,716 shares of the biotechnology company’s stock after purchasing an additional 1,570 shares during the quarter. California State Teachers Retirement System owned 0.12% of Spark Therapeutics worth $3,809,000 at the end of the most recent quarter.
Other hedge funds also recently modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in Spark Therapeutics by 15.0% in the third quarter. JPMorgan Chase & Co. now owns 1,848,988 shares of the biotechnology company’s stock worth $164,986,000 after purchasing an additional 241,016 shares during the last quarter. Ameriprise Financial Inc. boosted its holdings in Spark Therapeutics by 6.0% in the third quarter. Ameriprise Financial Inc. now owns 207,360 shares of the biotechnology company’s stock worth $18,489,000 after purchasing an additional 11,785 shares during the last quarter. BlackRock Inc. boosted its holdings in Spark Therapeutics by 11.6% in the second quarter. BlackRock Inc. now owns 2,053,734 shares of the biotechnology company’s stock worth $122,689,000 after purchasing an additional 213,520 shares during the last quarter. Amundi Pioneer Asset Management Inc. purchased a new stake in Spark Therapeutics in the third quarter worth approximately $5,286,000. Finally, Principal Financial Group Inc. boosted its holdings in Spark Therapeutics by 23.8% in the third quarter. Principal Financial Group Inc. now owns 54,088 shares of the biotechnology company’s stock worth $4,822,000 after purchasing an additional 10,399 shares during the last quarter. Institutional investors own 94.91% of the company’s stock.
Spark Therapeutics Inc (NASDAQ:ONCE) opened at $50.56 on Monday. The firm has a market cap of $1,870.00 and a price-to-earnings ratio of -7.02. Spark Therapeutics Inc has a one year low of $41.06 and a one year high of $91.75.
Spark Therapeutics (NASDAQ:ONCE) last issued its quarterly earnings results on Tuesday, November 7th. The biotechnology company reported ($1.90) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.79) by ($0.11). Spark Therapeutics had a negative return on equity of 60.01% and a negative net margin of 1,090.11%. The business had revenue of $1.90 million for the quarter, compared to analysts’ expectations of $1.40 million. During the same quarter in the prior year, the business earned ($1.07) EPS. The company’s revenue was up 45.8% compared to the same quarter last year. analysts expect that Spark Therapeutics Inc will post -7.55 earnings per share for the current year.
In related news, CEO Jeffrey D. Marrazzo sold 20,000 shares of Spark Therapeutics stock in a transaction on Monday, November 13th. The shares were sold at an average price of $71.54, for a total transaction of $1,430,800.00. Following the transaction, the chief executive officer now owns 250,000 shares in the company, valued at approximately $17,885,000. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Katherine A. High sold 5,000 shares of Spark Therapeutics stock in a transaction on Tuesday, October 31st. The shares were sold at an average price of $83.30, for a total transaction of $416,500.00. Following the transaction, the insider now owns 215,000 shares in the company, valued at approximately $17,909,500. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 62,309 shares of company stock worth $4,621,085. 7.30% of the stock is owned by corporate insiders.
Several brokerages recently issued reports on ONCE. Wedbush upgraded shares of Spark Therapeutics from an “underperform” rating to a “neutral” rating and dropped their target price for the stock from $65.00 to $50.00 in a report on Tuesday, December 12th. They noted that the move was a valuation call. SunTrust Banks raised their target price on shares of Spark Therapeutics to $113.00 and gave the stock a “buy” rating in a report on Thursday. Leerink Swann cut shares of Spark Therapeutics from an “outperform” rating to a “market perform” rating and set a $49.00 target price on the stock. in a report on Tuesday, December 12th. BMO Capital Markets set a $89.00 price target on shares of Spark Therapeutics and gave the stock a “buy” rating in a research note on Tuesday, October 10th. Finally, Raymond James Financial reiterated a “buy” rating on shares of Spark Therapeutics in a research note on Tuesday, December 19th. Two research analysts have rated the stock with a sell rating, five have given a hold rating and fifteen have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and an average target price of $76.03.
COPYRIGHT VIOLATION NOTICE: This piece was first posted by Transcript Daily and is the sole property of of Transcript Daily. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of US & international copyright and trademark legislation. The correct version of this piece can be read at https://transcriptdaily.com/2018/01/08/california-state-teachers-retirement-system-raises-position-in-spark-therapeutics-inc-once.html.
Spark Therapeutics Company Profile
Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.
Want to see what other hedge funds are holding ONCE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Spark Therapeutics Inc (NASDAQ:ONCE).
Receive News & Ratings for Spark Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.